XM does not provide services to residents of the United States of America.
B
B

Biogen

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Marvell Technology Inc MRVL.OQ +4.7% Trade Desk Inc TTD.OQ +3.6% Moderna Inc MRNA.OQ +2.8% Intel Corp INTC.OQ +2.6% Dollar Tree Inc DLTR.OQ +2.2% Bottom Performers Percent Change Cisco Systems Inc CSCO.OQ -2.9% Constellation Energy Corp CEG.OQ -2.5% Lululemon Athletica Inc LULU.OQ -2.4% Biogen Inc BIIB.OQ -2.1% Broadcom Inc AVGO.OQ -1.9% The Nasdaq 100 .NDX lost 33.17 points, or 0
B
B
C
I
L
M
D
U
T

U.S. STOCKS CME Group, Meta, Coterra Energy

BUZZ-U.S. STOCKS ON THE MOVE-CME Group, Meta, Coterra Energy Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Dow crossed the 40,000 level for the first time on Thursday, notching a fresh all-time high and leading Wall Street gains a day after tepid inflation data bolstered hopes of interest-rate cuts.
A
B
C
C
G
U
U

Biogen, Ionis fall after pulling the plug on experimental ALS drug

BUZZ-Biogen, Ionis fall after pulling the plug on experimental ALS drug Updates ** Shares of Biogen BIIB.O fall 3% to $228.7 and Ionis Pharmaceuticals IONS.O decline 6.2% to $36.8 ** Biogen and partner Ionis to terminate development of their experimental treatment for amyotrophic lateral sclerosis (ALS) ** Decision comes after the drug, BIIB105, fa
B

Biogen falls after discontinuing development of ALS drug

BUZZ-Biogen falls after discontinuing development of ALS drug ** Shares of Biogen BIIB.O fall 1% to $232.8 in premarket trading ** Biogen and partner Ionis Pharmaceuticals IONS.O to terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) ** The decision comes after the drug, BIIB105, failed to show improvem
B

Biogen Shares Update on Angelman Syndrome Program

BRIEF-Biogen Shares Update on Angelman Syndrome Program May 16 (Reuters) - Biogen Inc BIIB.O : BIOGEN INC -IN ADDITION TO DISCONTINUING DEVELOPMENT OF BIIB105, ELECTED NOT TO EXERCISE ITS OPTION TO LICENSE AND LEAD DEVELOPMENT OF BIIB121 Source text for Eikon: [ID:] Further company coverage: BIIB.O
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.